StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Pentosidine

HCID 119593
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
124505-87-9
Standard-SMILES
N[C@@H](CCCCn1cccc2nc(NCCC[C@H](N)C(=O)O)nc1-2)C(=O)O
InChIKey
AYEKKSTZQYEZPU-RYUDHWBXSA-N
Summenformel
C17H26N6O4
Durchschnittliche Molmasse
378,4 g/mol
Monoisotopische Masse
378,20155333

Überblick

Pentosidine is an imidazopyridine having norleucine and ornithine residues attached via their side-chains at the 4- and 2-positions respectively. It has a role as a cross-linking reagent and a biomarker. It is an imidazopyridine and a non-proteinogenic L-alpha-amino acid.

Namen und Bezeichner

Bevorzugter Name
Pentosidine
IUPAC
(2S)-2-amino-6-[2-[[(4S)-4-amino-4-carboxybutyl]amino]imidazo[4,5-b]pyridin-4-yl]hexanoic acid
Englischer Name
(2S)-2-amino-6-[8-[[(4S)-4-amino-4-carboxy-butyl]amino]-2,7,9-triazabicyclo[4.3.0]nona-3,5,7,9-tetraen-2-yl]hexanoic acid
Summenformel
C17H26N6O4
Molmasse
378.43

Namen und Synonyme

Pentosidine124505-87-9BJ4I2X2CQJCHEBI:59951DTXSID601544174H-Imidazo(4,5-b)pyridine-4-hexanoic acid, alpha-amino-2-((4-amino-4-carboxybutyl)amino)-, (S-(R*,R*))-6-(2-{[(4S)-4-amino-4-carboxybutyl]amino}-4H-imidazo[4,5-b]pyridin-4-yl)-L-norleucine(2S)-2-amino-6-(2-{[(4S)-4-amino-4-carboxybutyl]amino}-4H-imidazo[4,5-b]pyridin-4-yl)hexanoic acid6-(2-(((4S)-4-Amino-4-carboxybutyl)amino)-4H-imidazo(4,5-b)pyridin-4-yl)-L-norleucine(2S)-2-amino-6-(2-(((4S)-4-amino-4-carboxybutyl)amino)-4H-imidazo(4,5-b)pyridin-4-yl)hexanoic acidRefChem:171499DTXCID6076908
Weitere Namen anzeigen
Pentosidine. TFA saltGefitinib Impurity 109Pentosidine formate saltPENTOSIDINE 2,2,2-TRIFLUOROACETATE4H-Imidazo[4,5-b]pyridine-4-hexanoic acid, α-amino-2-[[(4S)-4-amino-4-carboxybutyl]amino]-, (αS)-(2S)-2-amino-6-[8-[[(4S)-4-amino-4-carboxy-butyl]amino]-2,7,9-triazabicyclo[4.3.0]nona-3,5,7,9-tetraen-2-yl]hexanoic acid
MFCD11111968(2S)-2-amino-6-[2-[[(4S)-4-amino-4-carboxybutyl]amino]imidazo[4,5-b]pyridin-4-yl]hexanoic acidC17H26N6O4(S)-2-Amino-6-(2-(((S)-4-amino-4-carboxybutyl)amino)-4H-imidazo[4,5-b]pyridin-4-yl)hexanoic acidUNII-BJ4I2X2CQJ4H-Imidazo(4,5-b)pyridine-4-hexanoic acid, alpha-amino-2-(((4S)-4-amino-4-carboxybutyl)amino)-, (alphaS)-4H-Imidazo[4,5-b]pyridine-4-hexanoic acid, alpha-amino-2-[[(4S)-4-amino-4-carboxybutyl]amino]-, (alphaS)-Epitope ID:140093

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-4,7
Polarare Oberfläche (TPSA)
169 Ų
H-Brücken-Donoren
5
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
12
Schwere Atome
27
Formalladung
0
Komplexität
494

Experimentelle und physikochemische Eigenschaften

Physical DescriptionSolid

Physikochemische Eigenschaften

Siedepunkt
655.6 · 655.6±65.0 °C(Predicted)
Dichte
1.47 · 1.47±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
Löslichkeit
21.4 mg/ml; · DMF: 21.4 mg/ml; DMSO: 22.4 mg/ml; Ethanol: 31.3 mg/ml; PBS (pH 7.2): 10 mg/ml
Aggregatzustand
A crystalline solid
pka
2.5 · 2.50±0.24(Predicted)
Stabilität
Hygroscopic

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

TreatmentKidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored.
Health EffectsChronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease.
Exposure RoutesEndogenous, Ingestion, Dermal (contact)
Toxicity Summary · 1 Eintrag

Uremic toxins such as pentosidine are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869).

Signs and Symptoms · 1 Eintrag

As a uremic toxin, this compound can cause uremic syndrome. Uremic syndrome may affect any part of the body and can cause nausea, vomiting, loss of appetite, and weight loss. It can also cause changes in mental status, such as confusion, reduced awareness, agitation, psychosis, seizures, and coma. Abnormal bleeding, such as bleeding spontaneously or profusely from a very minor injury can also occur. Heart problems, such as an irregular heartbeat, inflammation in the sac that surrounds the heart (pericarditis), and increased pressure on the heart can be seen in patients with uremic syndrome. Shortness of breath from fluid buildup in the space between the lungs and the chest wall (pleural effusion) can also be present.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/MetabolitesUremic toxins tend to accumulate in the blood either through dietary excess or through poor filtration by the kidneys. Most uremic toxins are metabolic waste products and are normally excreted in the urine or feces.
MeSH Pharmacological Classification · 1 Eintrag

Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other.

Verwendung und Herstellung

UsesNaturally produced by the body (endogenous).
Anwendungen · 2 Einträge

BeschreibungAdvanced glycation end products (AGEs) are compounds formed by non-enzymatic chemical reactions following the bonding of sugars to proteins or lipids during diabetes, uremia, aging, rheumatic arthritis, and other conditions. A receptor for the AGEs (RAGE) binds certain members of this class to initiate cell signaling. Pentosidine is a well-characterized natural AGE that is often used as a biomarker for the production of all AGEs. While pentosidine can be measured in urine, the majority of this AGE is catabolized before excretion.

VerwendenA biochemical marker of bone turnover for management of metabolic bone diseases.

Ergänzende Hinweise

DefinitionChEBI: An imidazopyridine having norleucine and ornithine residues attached via their side-chains at the 4- and 2-positions respectively.

Zugehörige Reaktionen

4
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 249394
HRID 249394als Produkt
Reaktionsgleichung von HRID 249395
HRID 249395als Produkt
Reaktionsgleichung von HRID 374408
HRID 374408als Produkt
Reaktionsgleichung von HRID 374409
HRID 374409als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
124505-87-9
PubChem CID
119593
DTXSID
DTXSID60154417
ChEBI
CHEBI:59951
UNII
BJ4I2X2CQJ
Nikkaji
J481.628E
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Sicherheitsdaten

hs_code
2922498590